Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $0.53, $0.25 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $70.3 million versus the consensus estimate of $65.3 million.

Financial Guidance

For the year ending December 31, 2024, we continue to anticipate approximately $150 million to $175 million of Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense. Non-GAAP combined R&D and SG&A expense guidance does not include stock-based compensation as we are currently unable to confidently estimate Full Year 2024 stock-based compensation expense. As such, we have not provided a reconciliation from forecasted non-GAAP to forecasted GAAP combined R&D and SG&A Expense. This could materially affect the calculation of forward-looking GAAP combined R&D and SG&A Expense as it is inherently uncertain. Refer to Non-GAAP Financial Measures section below for additional information.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.